What is RNAi Technologies Market?
RNAi technology is the biological process of mRNA degradation induced by complementary sequences of double-stranded small interfering RNAs and suppression of target gene expression. This technology includes a method of producing highly potent and purified siRNAs directly from Escherichiacoli cells. It offers the promise of a reduced risk approach to insect pest control. Rising the application of RNAi in molecular diagnosis and its viability as a therapeutic technique drive the global market growth.
Highlights from RNAi Technologies Market Study
|Unit||Value (USD Million)|
|Key Companies Profiled||Dicerna Pharmaceuticals (United States), TransCode Therapeutics (United States), Inceptor Bio (United States), Kodikaz Therapeutic (United States), Spark Therapeutics (United States), Phio Pharmaceuticals (United States), Sirnaomics, Inc (United States), Alnylam Pharmaceuticals (United States), Sirion Biotech (Germany) and Silence Therapeutics (United Kingdom)|
The companies operating in this industry are focusing on efficient growth, improvement of operational efficiency and productivity, achieving high print and digital standards, and focus on maintaining sustainable development. The players are focusing on securing a leading position in this industry. They are continuously looking for the opportunity to reinforce their competitive advantage. Dicerna Pharmaceuticals (United States), TransCode Therapeutics (United States), Inceptor Bio (United States), Kodikaz Therapeutic (United States), Spark Therapeutics (United States), Phio Pharmaceuticals (United States), Sirnaomics, Inc (United States), Alnylam Pharmaceuticals (United States), Sirion Biotech (Germany) and Silence Therapeutics (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Nanode Therapeutics, Inc. (United States), Genevant Sciences (United States) and Arbutus Biopharma (Canada).
RNAi Technologies Market Segmentation:
|Application / End User||Oncology, Ocular disorders, Respiratory disorders and Liver diseases|
|Type||Micro RNA (miRNA) and Small Interfering RNA (siRNA)|
On the basis of geography, the market of RNAi Technologies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Public Concern over the Risk that many of These Chemicals pose to the Environment and to Human and Livestock Health
- Rising Molecular Diagnostics Applications, Cancer, and Genetic and Metabolic Disorders
- Introduction of Techniques for the Identification of Altered Cellular Molecules and Metabolites
- Stringent Regulations on the RNAi Technologies
- Growing Numbers of Research Groups and Biotechnology Industries can create Opportunities for the Market
- Application of RNAi Technologies is the Major Challenging Factor for the Players
Market Leaders & Development Strategies
In November 2021, Novo Nordisk announced the acquisition of Dicerna Pharmaceuticals. It is a strategic addition to Novo Nordisk’s research technology platforms and helps the strategy by the application of a broad range of technology platforms use around all of Novo Nordisk’s therapeutic focus areas. The acquisition of Dicerna accelerates Novo Nordisk’s research within RNAi and expands the usage of RNAi technology.
On 19th May 2022, TransCode Therapeutics announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF.
Key Target AudienceRNAi Technologies Providers, Regulatory Bodies, Potential Investors, New Entrants, Research and Development Institutes and Others